I now see that a forecast NPAT for 07/08 in excess of $14m was reported in the most recent Intersuisse report.Comforting that Mr. Lange is confirming that value in his proposed presentations over the next few days.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%